Shanghai MicroPort Endovascular MedTech Co., Ltd.

SHSE:688016 Stock Report

Market Cap: CN¥12.6b

Shanghai MicroPort Endovascular MedTech Future Growth

Future criteria checks 5/6

Shanghai MicroPort Endovascular MedTech is forecast to grow earnings and revenue by 26.7% and 23.9% per annum respectively. EPS is expected to grow by 25.7% per annum. Return on equity is forecast to be 17.6% in 3 years.

Key information

26.7%

Earnings growth rate

25.67%

EPS growth rate

Medical Equipment earnings growth24.8%
Revenue growth rate23.9%
Future return on equity17.61%
Analyst coverage

Good

Last updated02 Sep 2025

Recent future growth updates

Recent updates

A Look At The Fair Value Of Shanghai MicroPort Endovascular MedTech Co., Ltd. (SHSE:688016)

Mar 24
A Look At The Fair Value Of Shanghai MicroPort Endovascular MedTech Co., Ltd. (SHSE:688016)

Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Shares Lagging The Market But So Is The Business

Jan 03
Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Shares Lagging The Market But So Is The Business

Investors Met With Slowing Returns on Capital At Shanghai MicroPort Endovascular MedTech (SHSE:688016)

Dec 16
Investors Met With Slowing Returns on Capital At Shanghai MicroPort Endovascular MedTech (SHSE:688016)

Calculating The Fair Value Of Shanghai MicroPort Endovascular MedTech Co., Ltd. (SHSE:688016)

Nov 27
Calculating The Fair Value Of Shanghai MicroPort Endovascular MedTech Co., Ltd. (SHSE:688016)

Shanghai MicroPort Endovascular MedTech's (SHSE:688016) Attractive Earnings Are Not All Good News For Shareholders

Nov 06
Shanghai MicroPort Endovascular MedTech's (SHSE:688016) Attractive Earnings Are Not All Good News For Shareholders

There's No Escaping Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Muted Earnings Despite A 31% Share Price Rise

Oct 01
There's No Escaping Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Muted Earnings Despite A 31% Share Price Rise

Earnings Miss: Shanghai MicroPort Endovascular MedTech Co., Ltd. Missed EPS By 16% And Analysts Are Revising Their Forecasts

Aug 29
Earnings Miss: Shanghai MicroPort Endovascular MedTech Co., Ltd. Missed EPS By 16% And Analysts Are Revising Their Forecasts

Shanghai MicroPort Endovascular MedTech (SHSE:688016) Will Want To Turn Around Its Return Trends

Aug 15
Shanghai MicroPort Endovascular MedTech (SHSE:688016) Will Want To Turn Around Its Return Trends

Investors Don't See Light At End Of Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Tunnel

Jun 29
Investors Don't See Light At End Of Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Tunnel

These 4 Measures Indicate That Shanghai MicroPort Endovascular MedTech (SHSE:688016) Is Using Debt Safely

Apr 29
These 4 Measures Indicate That Shanghai MicroPort Endovascular MedTech (SHSE:688016) Is Using Debt Safely

Shanghai MicroPort Endovascular MedTech's (SHSE:688016) Earnings Are Weaker Than They Seem

Apr 09
Shanghai MicroPort Endovascular MedTech's (SHSE:688016) Earnings Are Weaker Than They Seem

Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Business Is Trailing The Market But Its Shares Aren't

Mar 25
Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Business Is Trailing The Market But Its Shares Aren't

Earnings and Revenue Growth Forecasts

SHSE:688016 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20272,1808864918784
12/31/20261,9007943827406
12/31/20251,5606443566606
6/30/20251,13441388350N/A
3/31/20251,180447-73202N/A
12/31/20241,206502161374N/A
9/30/20241,268657390606N/A
6/30/20241,353616437636N/A
3/31/20241,260552458651N/A
12/31/20231,187492368558N/A
9/30/20231,121444166398N/A
6/30/20231,05942122369N/A
3/31/2023924358-10308N/A
12/31/202289735740334N/A
9/30/2022839367133340N/A
6/30/2022781346276362N/A
3/31/2022745338242337N/A
12/31/2021685316211300N/A
9/30/2021652302248299N/A
6/30/2021618279255291N/A
3/31/2021569257239269N/A
12/31/2020470215191217N/A
9/30/2020414192148174N/A
6/30/2020377177142166N/A
3/31/2020341156133154N/A
12/31/2019334142122143N/A
9/30/2019306127117138N/A
6/30/201928211584117N/A
3/31/2019257103N/A118N/A
12/31/201823191N/A107N/A
12/31/201716563N/A69N/A
12/31/201612541N/A30N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 688016's forecast earnings growth (26.7% per year) is above the savings rate (2.6%).

Earnings vs Market: 688016's earnings (26.7% per year) are forecast to grow faster than the CN market (26.3% per year).

High Growth Earnings: 688016's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 688016's revenue (23.9% per year) is forecast to grow faster than the CN market (14.1% per year).

High Growth Revenue: 688016's revenue (23.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 688016's Return on Equity is forecast to be low in 3 years time (17.6%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/28 01:05
End of Day Share Price 2025/10/28 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Shanghai MicroPort Endovascular MedTech Co., Ltd. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pei ChengChina Galaxy Securities Co., Ltd.
Yuan GaoChina International Capital Corporation Limited
Bo YuChina International Capital Corporation Limited